DJIA 17,798.49 -14.90 -0.08%
NASDAQ 5,127.53 11.38 0.22%
S&P 500 2,090.11 1.24 0.06%
market minute promo

AbbVie Inc. (NYSE: ABBV)

60.00 -0.29 (-0.48%)

Quote as of

company name or ticker

Recent Quotes

ABBV $60.00 -0.48%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $60.17
Previous Close $60.29
Daily Range $59.61 - $60.45
52-Week Range $45.45 - $71.60
Market Cap $98.1B
P/E Ratio 32.95
Dividend (Yield) $2.28 (3.8%)
Ex-Dividend Date
Dividend Pay Date
Volume 2,404,142
Average Daily Volume 10,858,350
Current FY EPS $4.29



AbbVie Inc. (ABBV) Description

AbbVie Inc. Website:

News & Commentary

Amgen Inc. Takes Aim at AbbVie Inc.

Amgen has filed an application for approval of its biosimilar to AbbVie's top-selling Humira.

Amgen Seeks FDA Approval for First Biosimilar of Humira

Amgen Invites AbbVie To Dance For Humira Biosimilar

Gilead Sciences Grabs 4 Regulatory Wins -- but Does It Matter?

Gilead Sciences has announced four new regulatory approvals since the start of the quarter, but will they move the company's financials?

Tracking Larry Robbins' Glenview Capital Management Portfolio - Q3 2015 Update

Can Pfizer Live Without Television?

A proposed ban on direct-to-consumer prescription drug advertising could spell trouble for the industry's biggest ad spender.

Clinton's Price Caps Are A Non-Starter: Liana Moussatos Of Wedbush Securities

Zacks Industry Outlook Highlights: Valeant, Pfizer, Allergan, AbbVie and Gilead

9 Stocks to Avoid in December and Beyond

Can Merck & Co. Take Down Gilead Sciences?

Harvoni still dominates the hepatitis C space, but new competition from Old Pharma is on the way.

See More ABBV News...